Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions. The company's lead investigational product is the LOMECEL-B, a cell-based therapy product that is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young healthy adult donors. It is conducting Phase 1 and 2 clinical trials in various indications, such as aging frailty, alzheimer's disease, metabolic syndrome, acute respiratory distress syndrome, and hypoplastic left heart syndrome. The company was incorporated in 2014 and is based in Miami, Florida.

Longeveron Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

MR. JHAVERI HAS OVER 25 YEARS OF EXPERIENCE IN CAPITAL MARKETS, CORPORATE FINANCE, BUSINESS DEVELOPMENT AND INVESTOR RELATIONS, INCLUDING MORE THAN 15 YEARS IN THE BIOTECH SECTOR MIAMI, AUG. 19, 2026 (GLOBE NEWSWIRE) -- LONGEVERON INC. (NASDAQ: LGVN), A CLINICAL STAGE BIOTECHNOLOGY COMPANY DEVELOPING CELLULAR THERAPY FOR LIFE-THREATENING, RARE PEDIATRIC AND CHRONIC AGING-RELATED CONDITIONS, TODAY ANNOUNCED THAT THE COMPANY HAS APPOINTED NIRAV JHAVERI, CFA, TO THE COMPANY'S EXECUTIVE LEADERSHIP TEAM IN THE ROLE OF CHIEF FINANCIAL OFFICER (CFO), PRINCIPAL FINANCIAL OFFICER AND PRINCIPAL ACCOUNTING OFFICER. HE SUCCEEDS MARIE WASHBURN WHO STEPPED INTO THE ROLE FOLLOWING THE RETIREMENT OF THE PRIOR CFO.

LONGEVERON APPOINTS NIRAV JHAVERI AS CHIEF FINANCIAL OFFICER

ON TRACK FOR SEPTEMBER 2026 TOP-LINE RESULTS FROM PHASE 2B CLINICAL TRIAL (ELPIS II) EVALUATING LAROMESTROCEL AS A POTENTIAL ADJUNCT TREATMENT FOR HYPOPLASTIC LEFT HEART SYNDROME (HLHS), A RARE PEDIATRIC DISEASE AND ORPHAN-DESIGNATED INDICATION LONGEVERON SELECTED AS A FINALIST AND MILESTONE 2 AWARDEE FOR THE XPRIZE HEALTHSPAN COMPETITION BASED ON PUBLISHED CLINICAL TRIAL RESULTS WHICH INDICATED LAROMESTROCEL INCREASED 6-MINUTE WALK DISTANCE IN PATIENTS WITH AGING FRAILTY THREE NEW INDEPENDENT DIRECTORS JOIN LONGEVERON'S BOARD OF DIRECTORS COMPANY TO HOST CONFERENCE CALL AND WEBCAST TODAY AT 4:30 P.M. ET MIAMI, AUG. 12, 2026 (GLOBE NEWSWIRE) -- LONGEVERON INC. (NASDAQ: LGVN), A CLINICAL STAGE BIOTECHNOLOGY COMPANY DEVELOPING CELLULAR THERAPY FOR LIFE-THREATENING, RARE PEDIATRIC AND CHRONIC AGING-RELATED CONDITIONS, TODAY REPORTED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2026 AND PROVIDED A BUSINESS UPDATE.

LONGEVERON ANNOUNCES 2026 SECOND QUARTER FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

LONGEVERON SELECTED AS A MILESTONE 2 AWARDEE BASED ON PUBLISHED CLINICAL TRIAL RESULTS WHICH DEMONSTRATED LAROMESTROCEL INCREASED 6-MINUTE WALK DISTANCE IN PATIENTS WITH AGING-RELATED FRAILTY MIAMI, AUG. 11, 2026 (GLOBE NEWSWIRE) -- LONGEVERON INC. (NASDAQ: LGVN), A CLINICAL-STAGE REGENERATIVE MEDICINE BIOTECHNOLOGY COMPANY DEVELOPING CELLULAR THERAPIES FOR LIFE-THREATENING AND CHRONIC AGING-RELATED CONDITIONS, TODAY ANNOUNCED THAT IT HAS BEEN SELECTED FROM OVER 600 WORLDWIDE APPLICANTS TO ADVANCE TO THE FINAL PHASE OF THE XPRIZE HEALTHSPAN COMPETITION AS A MILESTONE 2 AWARDEE TEAM. LONGEVERON WILL RECEIVE THE $1,000,000 MILESTONE 2 AWARD TO BE USED TOWARDS THE FUTURE COMPETITION CLINICAL TRIAL IN ACCORDANCE WITH THE XPRIZE COMPETITION RULES, WITH THE OPPORTUNITY TO COMPETE FOR THE XPRIZE GRAND PRIZE OF UP TO $81 MILLION.

LONGEVERON NAMED A FINALIST TEAM AND WILL RECEIVE A $1,000,000 MILESTONE 2 AWARD FOR THE XPRIZE HEALTHSPAN GLOBAL COMPETITION

MIAMI, FLA., AUG. 03, 2026 (GLOBE NEWSWIRE) -- LONGEVERON INC. (NASDAQ: LGVN), A CLINICAL STAGE REGENERATIVE MEDICINE BIOTECHNOLOGY COMPANY DEVELOPING CELLULAR THERAPIES FOR LIFE-THREATENING AND CHRONIC AGING-RELATED CONDITIONS, TODAY ANNOUNCED THAT IT WILL REPORT 2026 SECOND QUARTER FINANCIAL RESULTS AND PROVIDE A BUSINESS UPDATE ON WEDNESDAY, AUGUST 12, 2026 AFTER THE U.S. FINANCIAL MARKETS CLOSE.

LONGEVERON TO REPORT 2026 SECOND QUARTER FINANCIAL RESULTS AND HOST CONFERENCE CALL ON AUGUST 12, 2026

MIAMI, JULY 23, 2026 (GLOBE NEWSWIRE) -- LONGEVERON INC. (NASDAQ: LGVN) A CLINICAL STAGE BIOTECHNOLOGY COMPANY DEVELOPING CELLULAR THERAPY FOR LIFE-THREATENING, RARE PEDIATRIC AND CHRONIC AGING-RELATED CONDITIONS, TODAY ANNOUNCED THAT DEBORAH D. ASCHEIM, M.D.

DEBORAH D. ASCHEIM, M.D. ELECTED TO LONGEVERON BOARD OF DIRECTORS

POSTER PRESENTATION AT THE 2026 ALZHEIMER'S ASSOCIATION INTERNATIONAL CONFERENCE (AAIC) ENTITLED LAROMESTROCEL STABILIZES BRAIN INFLAMMATION IN KEY ALZHEIMER'S DISEASE GRAY AND WHITE MATTER REGIONS AS ASSESSED USING FREE WATER MRI PRESENTED AT JULY 13TH IN PERSON POSTER PRESENTATION SESSION RESULTS SUPPORT A CLINICALLY RELEVANT AND LONG-LASTING ANTI-INFLAMMATORY MECHANISM OF ACTION OF LAROMESTROCEL IN GRAY AND WHITE MATTER OF THE BRAIN, INDICATE POTENTIAL BLOOD BIOMARKER CORRELATES WITH CLINICAL OUTCOMES, AND SUPPORT CONTINUED CLINICAL DEVELOPMENT OF LAROMESTROCEL FOR ALZHEIMER'S DISEASE LONGEVERON HAS RECEIVED U.S. FDA RMAT DESIGNATION FOR ITS ALZHEIMER'S DISEASE PROGRAM AND HAS ALIGNED ON A PHASE 3 STUDY DESIGN MIAMI, JULY 13, 2026 (GLOBE NEWSWIRE) -- LONGEVERON INC. (NASDAQ: LGVN), A CLINICAL STAGE BIOTECHNOLOGY COMPANY DEVELOPING CELLULAR THERAPY FOR LIFE-THREATENING, RARE PEDIATRIC AND CHRONIC AGING-RELATED CONDITIONS, TODAY ANNOUNCED THAT ADDITIONAL ANALYSIS OF DATA FROM THE PHASE 2A CLINICAL TRIAL EVALUATING ITS STEM CELL THERAPY LAROMESTROCEL IN MILD ALZHEIMER'S DISEASE (AD) IS BEING PRESENTED IN A POSTER PRESENTATION AT THE 2026 ALZHEIMER'S ASSOCIATION INTERNATIONAL CONFERENCE (AAIC), BEING HELD JULY 12-15, 2026 IN LONDON, UNITED KINGDOM AND ONLINE. RESULTS PRESENTED IN LAROMESTROCEL STABILIZES BRAIN INFLAMMATION IN KEY ALZHEIMER'S DISEASE GRAY AND WHITE MATTER REGIONS AS ASSESSED USING FREE WATER MRI PROVIDE SUPPORT FOR A CLINICALLY RELEVANT AND DURABLE ANTI-INFLAMMATORY MECHANISM OF ACTION OF LAROMESTROCEL IN GRAY AND WHITE MATTER AND INDICATE POTENTIAL BLOOD BIOMARKER CORRELATES.

LONGEVERON ANNOUNCES PRESENTATION OF CLINICAL DATA AT THE 2026 ALZHEIMER'S ASSOCIATION INTERNATIONAL CONFERENCE (AAIC) THAT INDICATE ITS CELLULAR THERAPY LAROMESTROCEL REDUCED NEUROINFLAMMATION IN PATIENTS WITH ALZHEIMER'S DISEASE

MS. WASHBURN HAS OVER 20 YEARS OF EXPERIENCE IN LEADERSHIP ROLES IN THE PHARMACEUTICAL AND BIOTECH SECTORS CORPORATE FOCUS ON DELIVERING TOP-LINE RESULTS FROM THE PHASE 2B CLINICAL TRIAL EVALUATING ITS STEM CELL THERAPY IN HYPOPLASTIC LEFT HEART SYNDROME (HLHS), ANTICIPATED IN THE THIRD QUARTER OF 2026 MIAMI, JULY 06, 2026 (GLOBE NEWSWIRE) -- LONGEVERON INC. (NASDAQ: LGVN) A CLINICAL STAGE BIOTECHNOLOGY COMPANY DEVELOPING CELLULAR THERAPY FOR LIFE-THREATENING, RARE PEDIATRIC AND CHRONIC AGING-RELATED CONDITIONS, TODAY ANNOUNCED THAT THE COMPANY HAS APPOINTED MARIE WASHBURN TO THE COMPANY'S EXECUTIVE LEADERSHIP TEAM IN THE ROLE OF SENIOR VICE PRESIDENT AND CHIEF FINANCIAL OFFICER (CFO), PRINCIPAL FINANCIAL OFFICER AND PRINCIPAL ACCOUNTING OFFICER, EFFECTIVE JULY 13, 2026. SHE SUCCEEDS LISA LOCKLEAR WHO, AS PREVIOUSLY ANNOUNCED, IS STEPPING DOWN TO PURSUE BOARD OPPORTUNITIES AND OTHER PROFESSIONAL AND PERSONAL INTERESTS.

Longeveron Inc.

LGVN

Price

Financial Reports

No items found.

Press Releases

Longeveron Inc.

LGVN.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

LGVN